Skip to main content
SpringerLink
Log in

Treatment of Acute Myeloid Leukemia in Children

  • Chapter
Treatment of Acute Leukemias

Part of the book series: Current Clinical Oncology ((CCO))

  • 169 Accesses

Abstract

Acute myelogenous, or myeloid, leukemia (AML) in children represents approx 20% of the acute leukemias. With some minor exceptions, the biology of AML is similar in children and adults. Although AML is much more resistant to chemotherapy than acute lymphoblastic leukemia (ALL), treatment results in childhood AML have improved considerably over the last 20 yr (Fig. 1) (1,2). With intensive induction chemotherapy, 80–90% of children achieve complete remission (CR), which translates into a long-term disease-free survival (DFS) in as many as 50–60% of patients. The strategy of remission induction with the aim of restoring the normal bone marrow function, thus achieving CR, is widely accepted, whereas the options for postremission therapy are still controversial.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council’s 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood 1997;89:2311–2318.

    PubMed  CAS  Google Scholar 

  2. Woods WG, Kobrinsky N, Buckley J, et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Children’s Cancer Group pilot study. J Clin Oncol 1993;11:1448–1457.

    PubMed  CAS  Google Scholar 

  3. Zander AR, Berger C, Kroger N, et al. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Clin Cancer Res 1997;3:2671–2675.

    PubMed  CAS  Google Scholar 

  4. Burnett AK, Goldstone AH, Stevens RM, et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children’s Leukaemia Working Parties. Lancet 1998;351:700–708.

    Article  PubMed  CAS  Google Scholar 

  5. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. Br J Haematol 1976;33: 451–458.

    Article  PubMed  CAS  Google Scholar 

  6. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985;103:626–629.

    Google Scholar 

  7. Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:460–462.

    PubMed  CAS  Google Scholar 

  8. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AMLMO). Br J Haematol 1991;78:325–329.

    Article  PubMed  CAS  Google Scholar 

  9. Creutzig U, Cantú Rajnoldi A, Ritter J et al. Myelodysplastic syndromes in childhood: report of 21 patients from Italy and West-Germany. Am J Pediatr Hematol Oncol 1987;9:324–330.

    Article  PubMed  CAS  Google Scholar 

  10. Hasle H, Jacobsen BB, Pedersen NT. Myelodysplastic syndromes in childhood: a population based study of nine cases. Br J Haematol 1992;81:495–498.

    Article  PubMed  CAS  Google Scholar 

  11. Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Br J Haematol 1999;104: 630–639.

    Article  PubMed  CAS  Google Scholar 

  12. Cheson BD, Cassileth PA, Head DR et al. Report of the National Cancer Institute-sponsored workshop on definitions and response in acute myeloid leukemia. J Clin Oncol 1990;8:813–819.

    PubMed  CAS  Google Scholar 

  13. Neale GA, Coustan SE, Pan Q, et al. Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 1999;13:1221–1226.

    Article  PubMed  CAS  Google Scholar 

  14. Campana D, Coustan-Smith E. Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 1999; 38:139–152.

    Article  PubMed  CAS  Google Scholar 

  15. Diverio D, Pandolfi PP, Biondi A, et al. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission. Blood 1993;82:3556–3559.

    PubMed  CAS  Google Scholar 

  16. Lemons RS, Keller S, Gietzen D, et al. Acute promyelocytic leukemia. J Pediatr Hematol Oncol 1995;17:198–210.

    Article  PubMed  CAS  Google Scholar 

  17. Warrell RM, Frankel SR, Miller WH, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991;324:1385–1393.

    Article  PubMed  Google Scholar 

  18. Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 1981;58:1203–1212.

    PubMed  CAS  Google Scholar 

  19. Bishop JF, Matthews JP, Young GA, et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996;87:1710–1717.

    PubMed  CAS  Google Scholar 

  20. Büchner T, Hiddemann W, Löffler G, et al. Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group. Semin Hematol 1991;28:76–79.

    PubMed  Google Scholar 

  21. Büchner T, Hiddemann W, Wörmann B, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999;93:4116–4124.

    PubMed  Google Scholar 

  22. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AMLBFM-78. Blood 1990;75:1932–1940.

    PubMed  CAS  Google Scholar 

  23. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991;77:1666–1674.

    PubMed  CAS  Google Scholar 

  24. Arlin Z, Case-DC J, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL). Lederle Cooperative Group. Leukemia 1990;4: 177–183.

    PubMed  CAS  Google Scholar 

  25. The AML Collaborative Group. A systemic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 1998;103:100–109.

    Article  Google Scholar 

  26. Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. Leukemia 2001;15:348–354.

    Article  PubMed  CAS  Google Scholar 

  27. Weinstein H, Mayer R, Rosenthal D, et al. Chemotherapy for acute myelogenous leukemia in children and adults. VAPA update. Blood 1983;62:315–319.

    PubMed  CAS  Google Scholar 

  28. Creutzig U, Ritter J, Zimmermann M, Schellong G, for the AMLBFM Study Group. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia (AML): unexpected results of the childhood AML Study BFM-87. J Clin Oncol 1993; 11:279–286.

    PubMed  CAS  Google Scholar 

  29. Lie SO, Clausen N, Gustafson G, et al. A reduction in therapy intensity may improve outcome in childhood AML. Med Pediatr Oncol 1997;29:437.

    Google Scholar 

  30. Stevens RF, Hann IM, Wheatley K, Gray RG, on behalf of the MRC Childhood Leukaemia Working Party. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukaemia: results of the United Kingdom Medical Research Council’s 10th AML trial. Br J Haematol 1998;101:130–140.

    Article  PubMed  CAS  Google Scholar 

  31. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998;58:4173–4179.

    PubMed  CAS  Google Scholar 

  32. Cassileth PA, Lynch E, Hines JD, et al. Varying intensity of postremission therapy in acute leukemia. Blood 1992;79:1924–1930.

    PubMed  CAS  Google Scholar 

  33. Wells RJ, Woods WG, Lampkin BC, et al. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Children’s Cancer Group. J Clin Oncol 1993;11:538–545.

    PubMed  CAS  Google Scholar 

  34. Feig SA, Lampkin B, et al. Outcome of BMT during first complete remission of AML: a comparison of two sequential studies by the Children’s Cancer Group. Bone Marrow Transplant 1993;12: 65–71.

    PubMed  CAS  Google Scholar 

  35. Lange B, Woods W, Lampkin B, et al. Childrens Cancer Group transplant trials for acute myeloid leukemia in children: a crossstudy analysis of CCG-251, CCG-213, CCG-2861, and CCG-2891. Haematol Blood Transf 1993;36:476–485.

    Google Scholar 

  36. Creutzig U, Bender-Götze C, Klingebiel T, et al. [Comparison of postremission chemtherapy and allogeneic bone marrow transplantation in first complete remission in children with acute myelogenous leukemia in studies AML-BFM-83 and AML-BFM-87. Matched pair analysis]. Klin Pädiatr 1992;204:246–252.

    Article  PubMed  CAS  Google Scholar 

  37. Creutzig U, Ritter J, Zimmermann M, et al. Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt- Munster 93. J Clin Oncol 2001;19:2705–2713.

    PubMed  CAS  Google Scholar 

  38. Dahl GV, Kalwinsky DK, Mirro J Jr, et al. Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission. J Clin Oncol 1990;8:295–303.

    PubMed  CAS  Google Scholar 

  39. Riley LC, Hann IM, Wheatley K, Stevens RF. Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol 1999;106: 436–444.

    Google Scholar 

  40. Michel G, Gluckman E, Blaise D, et al. Improvement in outcome for children receiving allogeneic bone marrow transplantation in first remission of acute myeloid leukemia: a report from the Groupe d’Etude des Greffes de Moelle Osseuse. J Clin Oncol 1992; 10:1865–1869.

    PubMed  CAS  Google Scholar 

  41. Appelbaum FR, Fisher LD, Thomas ED. Chemotherapy versus marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. Blood 1988;72:179–184.

    PubMed  CAS  Google Scholar 

  42. Appelbaum FR. Is there a best transplant conditioning regimen for acute myeloid leukemia? Leukemia 2000;14:497–501.

    Article  PubMed  CAS  Google Scholar 

  43. Leahey AM, Teunissen H, Friedman DL, et al. Late effects of chemotherapy compared to bone marrow transplantation in the treatment of pediatric acute myeloid leukemia and myelodysplasia. Med Pediatr Oncol 1999;32:163–169.

    Article  PubMed  CAS  Google Scholar 

  44. Chown SR, Marks DI, Cornish JM, et al. Unrelated donor bone marrow transplantation in children and young adults with acute myeloid leukaemia in remission. Br J Haematol 1997;99:36–40.

    Article  PubMed  CAS  Google Scholar 

  45. Busca A, Anasetti C, Anderson G, et al. Unrelated donor or autologous transplantation for treatment of acute leukemia. Blood 1994; 83:3077–3084.

    PubMed  CAS  Google Scholar 

  46. Ladenstein R, Peters C, Gadner H. The present role of bone marrow and stem cell transplantation in the therapy of children with acute leukemia. Ann NY Acad Sci 1997;824:38–64.

    Article  PubMed  CAS  Google Scholar 

  47. Hows J, Bradley BA, Gore S, et al. Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 1993;12:371–380.

    PubMed  CAS  Google Scholar 

  48. Gorin NC, Labopin M, Fouillard L, et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996;18:111–117.

    PubMed  CAS  Google Scholar 

  49. Yeager AM, Kaizer H, Santos GW, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo treatment with 4-hydroperoxycyclophosphamide. N Engl J Med 1986;315:141–147.

    Article  PubMed  CAS  Google Scholar 

  50. Gorin NC, Aegerter P, Auvert B, et al. Autologous bone marrow transplantation for acute myelogenous leukemia in first remission: a European survey of the role of marrow purging. Blood 1990; 75:1606–1614.

    PubMed  CAS  Google Scholar 

  51. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. N Engl J Med 1996;334:1428–1434.

    Article  PubMed  CAS  Google Scholar 

  52. Amadori S, Testi AM, Aricó M, et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol 1993;11:1046–1054.

    PubMed  CAS  Google Scholar 

  53. Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transplant 1998;22:865–872.

    Article  PubMed  CAS  Google Scholar 

  54. Baehner RL, Bernstein ID, Sather H, et al. Contrasting benefits of two maintenance programs following identical induction in children with acute nonlymphocytic leukemia: a report from the Children’s Cancer Study Group. Cancer Treat Rep 1984;68: 1269–1272.

    PubMed  CAS  Google Scholar 

  55. Pinkel D, Simone J, Hustu HO, Aur RJ. Nine years’ experience with “total therapy” of childhood acute lymphocytic leukemia. Pediatrics 1972;50:246–251.

    PubMed  CAS  Google Scholar 

  56. Dahl GV, Simone JV, Hustu HO, Mason C. Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia. Cancer 1978;42:2187–2192.

    Article  PubMed  CAS  Google Scholar 

  57. Grier HE, Gelber RD, Clavell LA, et al. Intensive sequential chemotherapy for children with acute myelogenous leukemia. Haematol Bluttransfus 1990;33:193–197.

    CAS  Google Scholar 

  58. Buckley JD, Chard RL, Baehner RL, et al. Improvement in outcome for children with acute nonlymphocytic leukemia. A report from the Children’s Cancer Study Group. Cancer 1989;63: 1457–1465.

    Article  PubMed  CAS  Google Scholar 

  59. Dastugue N, Payen C, Lafage Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 1995;9:1491–1498.

    PubMed  CAS  Google Scholar 

  60. Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia: associations with hyperleukocytosis and acute monocytic leukemia. Cancer 1987;60:3071–3079.

    Article  PubMed  CAS  Google Scholar 

  61. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council’s Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999;107:69–79.

    Article  PubMed  CAS  Google Scholar 

  62. Martinez Climent JA, Lane NJ, Rubin CM, et al. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia 1995;9:95–101.

    Google Scholar 

  63. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 1999;94: 3707–3716.

    PubMed  CAS  Google Scholar 

  64. Creutzig U, Ritter J, Vormoor J, et al. Transiente Myeloproliferation und akute myeloische Leukämie bei Säuglingen mit Morbus Down. Klin Padiatr 1990;202:253–257.

    Article  PubMed  CAS  Google Scholar 

  65. Robison LL, Nesbit MEJ, Sather HN, et al. Down syndrome and acute leukemia in children: a 10-year retrospective survey from Children’s Cancer Study Group. J Pediatr 1984;105:235–242.

    Article  PubMed  CAS  Google Scholar 

  66. Kojima S, Matsuyama T, Sato T, et al. Down’s syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction. Blood 1990;76:2348–2353.

    PubMed  CAS  Google Scholar 

  67. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down’s syndrome: a review. Pediatr Hematol Oncol 1987;4: 211–230.

    Article  PubMed  CAS  Google Scholar 

  68. Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Down’s syndrome. Leuk Res 1994;18:163–171.

    Article  PubMed  CAS  Google Scholar 

  69. Zipursky A, Poon A, Doyle J. Leukemia in Down syndrome. A review. Pediatr Hematol Oncol 1992;9:139–149.

    Article  PubMed  CAS  Google Scholar 

  70. Creutzig U, Ritter J, Vormoor J, et al. Myelodysplasia and acute myelogenous leukemia in Down’s syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia 1996;10: 1677–1686.

    PubMed  CAS  Google Scholar 

  71. Zipursky A, Wang H, Brown EJ, Squire J. Interphase cytogenetic analysis of in vivo differentiation in the myelodysplasia of Down syndrome. Blood 1994;84:2278–2282.

    PubMed  CAS  Google Scholar 

  72. Yumura-Yagi K, Hara J, Tawa A, Kawa-Ha K. Phenotypic characteristics of acute leukemia and transient megakaryocytic leukemia and transient abnormal myelopoiesis. Leuk Lymphom 1994;13: 393–400.

    Article  CAS  Google Scholar 

  73. Ravindranath Y, Abella E, Krischer JP, et al. Acute myeloid leukemia (AML) in Down’s syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 1992;80:2210–2214.

    PubMed  CAS  Google Scholar 

  74. Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood 1999;94:1393–1400.

    PubMed  CAS  Google Scholar 

  75. Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808–815.

    Article  PubMed  CAS  Google Scholar 

  76. Creutzig U, Baumann M. Spontaneous remission in neonates with Down’s syndrome and acute myelogenous leukemia-transient myeloproliferative disease. Onkologie 1998;21:124–128.

    Article  Google Scholar 

  77. Fenaux P, Castaigne S, Chomienne C, Dombret H, Degos L. All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 1992;6:64–67.

    PubMed  Google Scholar 

  78. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999; 94:1192–1200.

    PubMed  CAS  Google Scholar 

  79. Lo Coco F., Nervi C, Avvisati G, Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia 1998;12:1866–1880.

    Article  PubMed  CAS  Google Scholar 

  80. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell’ Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups. Blood 1997;90:1014–1021.

    PubMed  CAS  Google Scholar 

  81. Mrozek K, Heinonen K, de-la CA, Bloomfield CD. Clinical significance of cytogenetics in acute myeloid leukemia. Semin Oncol 1997;24:17–31.

    PubMed  CAS  Google Scholar 

  82. Ghaddar HM, Plunkett W, Kantarjian HM, et al. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 1994;8:1269–1274.

    PubMed  CAS  Google Scholar 

  83. Seymour JF, Juneja SK, Campbell LJ, et al. Secondary acute myeloid leukemia with inv(16): report of two cases following paclitaxel-containing chemotherapy and review of the role of intensified ara-C therapy. Leukemia 1999;13:1735–1740.

    Article  PubMed  CAS  Google Scholar 

  84. Tobelem G, Jacquillat C, Chastang C, et al. Acute monoblastic leukemia: a clinical and biological study of 74 cases. Blood 1980; 55:71–76.

    PubMed  CAS  Google Scholar 

  85. Weinstein H, Grier H, Gelber R et al. Postremission induction intensive sequential chemotherapy for children with AML-treatment results and prognostic factors. Hamatol Bluttransfus 1987; 30:88–92.

    CAS  Google Scholar 

  86. Nishikawa A, Nakamura Y, Nobori U, et al. Acute monocytic leukemia in children. Response to VP-16–213 as a single agent. Cancer 1987;60:2146–2149.

    Article  PubMed  CAS  Google Scholar 

  87. Cavalli F. VP16–213 (etoposide). A critical review of its activity. Cancer Chemother Pharmacol 1982;7:81–85.

    Article  PubMed  CAS  Google Scholar 

  88. Codegoni AM, Biondi A, Conter Vet al. Human monocytic leukemia expresses low levels of asparagine synthase and is potentially sensitive to L-asparaginase. Leukemia 1995;9:360–361.

    PubMed  CAS  Google Scholar 

  89. Zwaan ChM, Kaspers GJL, Pieters R, et al. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia. Blood 2000;96:2879–2885.

    PubMed  CAS  Google Scholar 

  90. Santana VM, Hurwitz CA, Blakley RL, et al. Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 1994; 84:1237–1242.

    PubMed  CAS  Google Scholar 

  91. Rots MG, Pieters R, Peters GJ, et al. Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates. Blood 1999;54:3121–3128.

    Google Scholar 

  92. Groch SN, Sayre GP, Heck FJ. Cerebral hemorrhage in leukemia. Arch Neurol 1960;2:439–451.

    Article  PubMed  CAS  Google Scholar 

  93. Sutor AH, Kremens B, Creutzig U, Ritter J, Schellong G. Haemostase- und Fibrinolyseparameter bei akuter myeloischer Leukämie (AML) im Kindesalter. In: Haemostase, Thrombophilie und Arteriosklerose. (van de Loo J, Asbeck F, eds.), Schattauer Verlag, 1982; pp.340–343.

    Google Scholar 

  94. Mann G, Reinhardt D, Ritter J, et al. Treatment with all-trans retinoid acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol 2001;80:417–422.

    Article  PubMed  CAS  Google Scholar 

  95. Boos J, Hohenlöchter B, Schulze-Westhoff P, et al. Intracellular retention of cytosine-arabinoside-triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia. Med Pediatr Oncol 1996;26:397–404.

    Article  PubMed  CAS  Google Scholar 

  96. Vandat L, Wong ET, Wile MJ, et al. Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia. Blood 1994;84:3429–3434.

    Google Scholar 

  97. Huhmann IM, Watzke HH, Geissler K, et al. FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia. Ann Hematol 1996;73:265–271.

    Article  PubMed  CAS  Google Scholar 

  98. Nokes TJ, Johnson S, Harvey D, Goldstone AH. FLAG is a useful regimen for poor prognosis adult myeloid leukaemias and myelodysplastic syndromes. Leuk Lymphoma 1997;27:93–101.

    PubMed  CAS  Google Scholar 

  99. Clavio M, Carrara P, Miglino M, et al. High efficacy of fludarabinecontaining therapy (FLAG-FLANG) in poor risk acute myeloid leukemia. Haematologica 1996;81:513–520.

    PubMed  CAS  Google Scholar 

  100. Griffin JD, Young D, Hermann F, et al. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 1986;67:1448–1453.

    PubMed  CAS  Google Scholar 

  101. Hoang T, Nara N, Wong G, et al. Effects of recombinant GM-CSF on the blast cells of acute myeloblastic leukemia. Blood 1986; 68:313–316.

    PubMed  CAS  Google Scholar 

  102. American Society of Clinical Oncology. Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 1996;14: 1957–1960.

    Google Scholar 

  103. Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colonystimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997;336: 1781–1787.

    Article  PubMed  CAS  Google Scholar 

  104. Moore JO, Dodge RK, Amrein PC, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood 1997;89:780–788.

    PubMed  CAS  Google Scholar 

  105. Geller RB. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 1996;14:1371–1382.

    PubMed  CAS  Google Scholar 

  106. Büchner T, Hiddemann W, Koenigsmann M, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 1991;78:1190–1197.

    PubMed  Google Scholar 

  107. Kaushansky K. Use of thrombopoietic growth factors in acute leukemia. Leukemia 2000;14:505–508.

    Article  PubMed  CAS  Google Scholar 

  108. Büchner T, Hiddemann W, Rottmann R, et al. GM-CSF in chemotherapy for newly diagnosed AML: multiple course priming and long-term administration compared to chemotherapy alone. Haematol Blood Transfus 1993;36:138–141.

    Google Scholar 

  109. Estey E, Thall PF, Kantarjian H, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 1992;79: 2246–2255.

    PubMed  CAS  Google Scholar 

  110. Thomas X, Fenaux P, Dombret H, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 1999;13:1214–1220.

    Article  PubMed  CAS  Google Scholar 

  111. Waxman S. Differentiation therapy in acute myelogenous leukemia (non-APL). Leukemia 2000;14:491–496.

    Article  PubMed  CAS  Google Scholar 

  112. Guidez F, Ivins S, Zhu J, et al. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZFRARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 1998;91:2634–2642.

    PubMed  CAS  Google Scholar 

  113. Zwiebel JA. New agents for acute myelogenous leukemia. Leukemia 2000;14:488–490.

    Article  PubMed  CAS  Google Scholar 

  114. Foon KA, Gale RP. Acute myelogenous leukemia: current status of therapy in adults. Recent Results Cancer Res 1984;93: 216–239.

    Article  PubMed  CAS  Google Scholar 

  115. Guillaume T, Rubinstein DB, Symann M. Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. Blood 1998;92:1471–1490.

    PubMed  CAS  Google Scholar 

  116. Wiernik PH, Dutcher JP, Todd M, Caliendo G, Benson L. Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. Am J Hematol 1994;47:41–44.

    Article  PubMed  CAS  Google Scholar 

  117. Meloni G, Vignetti M, Pogliani E, Invernizzi R, Allione B, Mirto S et al. Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer J Sci Am 1997;3(suppl 1):43–47.

    Google Scholar 

  118. Sievers EL, Appelbaum FR, Spielberger RT, et al. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93:3678–3684.

    PubMed  CAS  Google Scholar 

  119. Miller WH, Kakizuka A, Frankel SR. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1992; 89:2694–2698.

    Article  PubMed  CAS  Google Scholar 

  120. Kozu T, Miyoshi H, Shimizu K, et al. Junctions of the AML 1 / MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 1993;82:1270–1276.

    PubMed  CAS  Google Scholar 

  121. Jaeger U, Kusec R, Haas OA. Detection of AML 1 /ETO rearrangements in acute myeloid leukemia with a translocation t(8;21). Haematol Blood Transfus 1995;37:475–477.

    Google Scholar 

  122. Tobal K, Liu YJ. RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in longterm remission of APL. Leukemia 1998;12:1349–1354.

    Article  PubMed  CAS  Google Scholar 

  123. Lo Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999;94: 2225–2229.

    PubMed  Google Scholar 

  124. Vogler WR. Strategies in the treatment of acute myelogenous leukemia. Leuk Res 1992;16:1141–1153.

    Article  Google Scholar 

  125. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56–62.

    Article  PubMed  CAS  Google Scholar 

  126. Creutzig U, Reinhardt D, Zimmermann M, Klingebiel T, Gadner H. Intensive chemotherapy versus bone marrow transplantation in pediatric acute myeloid leukemia: a matter of controversies. Blood 2001;97:3671–3672.

    Article  PubMed  CAS  Google Scholar 

  127. Stahnke K, Boos J, Bender-Götze C, et al. Duration of first remission predicts remission rates and longterm survival in children with relapsed acute myelogenous leukemia. Leukemia 1998;12: 1543–1538.

    Article  Google Scholar 

  128. Mandelli F, Vegna ML, Avvisati G, et al. A randomized study of the efficacy of postconsolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA. Ann Hematol 1992;64:166–172.

    Article  PubMed  CAS  Google Scholar 

  129. Büchner T, Hiddemann W, Wörmann B, et al. Chemotherapy intensity and long-term outcome in AML. Haematol Blood Transfus 1993;36:513–518.

    Google Scholar 

  130. Büchner T. Acute leukemia. Curr Opin Hematol 1993;172–182.

    Google Scholar 

  131. Woods WG, Ruymann FB, Lampkin BC, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute non-lymphocytic leukemia. Cancer 1990;66:1106–1113.

    Article  PubMed  CAS  Google Scholar 

  132. Steuber CP, Humphrey GB, McMillan CW, Vietti TJ. Remission induction in acute myelogenous leukemia using cytosine arabino-side synchronization: a Southwest Oncology Group Study. Med Pediatr Oncol 1978;4:337–342.

    Article  PubMed  CAS  Google Scholar 

  133. Pui CH, Raimondi SC, Srivastava DK, et al. Prognostic factors in infants with acute myeloid leukemia. Leukemia 2000;14: 684–687.

    Article  PubMed  CAS  Google Scholar 

  134. Van-Dongen-Melman JE, De Groot A, Van Dongen JJ, Verhulst FC, Hahlen K. Cranial irradiation is the major cause of learning problems in children treated for leukemia and lymphoma: a comparative study. Leukemia 1997;11:1197–1200.

    Article  PubMed  CAS  Google Scholar 

  135. Reinhardt D, Thiele C, Creutzig U. Neuropsychological sequelae in irradiated/non-irradiated pediatric patients with AML. Blood 2000; 96(suppl 1):1387.

    Google Scholar 

  136. Gordon BG, Warkentin PI, Strandjord SE, et al. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation. Bone Marrow Transplant 1997;20:5–10.

    Article  PubMed  CAS  Google Scholar 

  137. Thomas X, Archimbaud E. Mitoxantrone in the treatment of acute myelogenous leukemia: a review. Hematol Cell Ther 1997;39: 63–74.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Ursula Creutzig
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St. Jude Children’s Research Hospital, University of Tennessee Health Science Center, Memphis, TN, USA

    Ching-Hon Pui MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Creutzig, U. (2003). Treatment of Acute Myeloid Leukemia in Children. In: Pui, CH. (eds) Treatment of Acute Leukemias. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-307-1_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-307-1_17

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-212-4

  • Online ISBN: 978-1-59259-307-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation